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 ABSTRACT |	 Residual	cyst	is	an	inflammatory	odontogenic	cyst	resultant	from	pulp	necrosis,	where	the	tooth	has	already	been	re-
moved.	Bisphosphonates	 are	drugs	used	 in	 the	prevention	and	 treatment	of	 bone	metabolism	diseases	with	 intense	
resorption	activity,	and	they	have	been	associated	with	osteonecrosis	of	the	jaws,	an	important	side	effect.	The	aim	of	
this	study	was	to	report	a	successful	surgical	treatment	of	a	residual	cyst	in	a	patient	who	had	previously	developed	jaw	
osteonecrosis	associated	with	sodium	alendronate	use.	We	emphasize	here	the	importance	of	safe	preoperative	proce-
dures	when	approaching	these	patients.
 DESCRIPTORS |	 Bisphosphonates;	Osteonecrosis;	Cysts.
 RESUMO | Excisão cirúrgica de cisto residual em um paciente com história prévia de osteonecrose associada ao uso de bisfosfonato: 
um relato de caso •	Cisto	residual	é	uma	lesão	odontogênica	inflamatória	resultante	de	necrose	pulpar,	em	local	de	extração	prévia.	
Os	bisfosfonatos	são	medicamentos	usados	na	prevenção	e	tratamento	de	doenças	caracterizadas	por	excessiva	reabsorção	óssea,	e	que	
têm	sido	associados	com	osteonecrose	dos	maxilares,	um	importante	efeito	colateral.	O	objetivo	deste	estudo	foi	relatar	um	tratamento	
cirúrgico	com	sucesso	de	um	cisto	residual	em	um	paciente	com	histórico	de	osteonecrose	mandibular	associada	ao	uso	de	alendronato	
de	sódio.	Cauteloso	manejo	deve	ser	creditado	quando	necessários	procedimentos	cirúrgicos	em	tais	grupos	de	pacientes.
 DESCRITORES |	 Bisfosfonatos;	Osteonecrose;	Cistos.
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INTRODUCTION
Bisphosphonates	are	a	group	of	drugs	that	have	
been	 used	 in	 the	 management	 of	 metabolic	 and	
oncologic	diseases	characterized	by	an	increase	of	
osteoclastic	 activity.	 In	 the	 clinical	 setting,	 these	
agents	 are	 available	 for	 oral	 and	 intravenous	 (IV)	
administration.1	The	first	one	is	primarily	used	for	
treatment	of	osteoporosis,	reducing	the	risk	of	ver-
tebral	and	non-vertebral	fractures.	When	adminis-
tered	by	IV	route,	 they	are	 indicated	 for	stabiliza-
tion	of	bone	metastasis	of	solid	tumors,	treatment	of	
bone	resorption	defects	 in	multiple	myeloma,	cor-
rection	of	hypercalcemia	and	in	the	management	of	
Paget’s	disease	and	fibrous	dysplasia.1	Additionally,	
in	2007,	Food	and	Drug	Administration	(FDA)	ap-
proved	 parenteral	 administration	 of	 zoledronic	
acid	for	management	of	osteoporosis.1
Adverse	 effects	 of	 bisphosphonate	 therapy	 are	
intimately	 related	 to	 type,	 frequency	 and	 route	 of	
drug	 administration.	 Firstly	 described	 in	 2003,	
bisphosphonate-related	 osteonecrosis	 of	 the	 jaws	
(BRONJ),	 now	 called	 medication-related	 osteo-
necrosis	of	 the	 jaw	(MRONJ)	 is	an	 important	side	
effect	 whose	 etiopathogenesis	 is	 not	 complete-
ly	known.2	 It	was	estimated	 that	up	 to	 12%	of	pa-
tients	 treated	with	 IV	 bisphosphonates	 for	 cancer	
could	 develop	 MRONJ.1	 Among	 patients	 taking	
oral	bisphosphonates,	this	condition	was	estimated	
at	0.1%.3
Clinically,	MRONJ	is	defined	as	an	area	of	expo-
sed	bone	in	the	maxillofacial	region	that	persists	for	
at	least	eight	weeks	in	a	patient	who	is	receiving	or	
has	been	exposed	to	a	bisphosphonate	and	has	not	
had	 radiation	 therapy	 to	 the	 craniofacial	 region.3 
Radiographic	 features	 cannot	 be	 distinguished	
from	 periapical	 lesions,	 osteomyelitis,	 primary	 or	
metastatic	 bone	 disease.4	 Microscopically,	 non-
-vital	bone	tissue,	chronic	 inflammatory	 infiltrate,	
bacteria	 colonization	 consistent	with	Actinomyces	
sp,	 and	 absence	 of	 osteoclasts	 are	 observed.	
Furthermore,	 intertrabecular	 fibrosis	 and	 inflam-
matory	 infiltrate	 within	 bone	marrow	 spaces	 can	
also	be	noted.5
The	 major	 goal	 of	 management	 for	 patients	
who	have	MRONJ	 is	 to	preserve	 the	quality	of	 life	
through	 controlling	 pain,	managing	 infection,	 and	
preventing	 the	development	of	new	areas	of	necro-
sis.4	Laboratory	tests	that	can	provide	the	intensity	
of	 collagen	 degradation,	 such	 as	 carboxy-terminal	
collagen	 crosslinks	 (CTX),	 even	 nonspecific,	 can	
provide	predictive	values	in	cases	that	need	maxillo-
facial	surgery.6 
The	 aim	of	 this	 study	 is	 to	 report	 a	 successful	
surgical	treatment	of	a	maxillary	residual	cyst	in	a	
patient	who	had	previously	developed	BRONJ	asso-
ciated	with	alendronate	use.
CASE REPORT
A	73-year-old	 female	patient	presented	with	a	
MRONJ	 in	 right	 mandible	 two	 months	 after	 ex-
traction	of	right	mandibular	first	and	second	pre-
molars.	 At	 that	 time,	 serum	 CTX	was	 20pg/mL,	
alendronate	therapy	was	withdrawn,	for	three	ye-
ars,	by	the	patient’s	physician,	and	medical	treat-
ment	for	MRONJ	was	started.	One	year	after	this,	
the	lesion	was	completely	healed.	Treatment	con-
sisted	of	oral	penicillin	and	mouthrinse	with	anti-
microbial	 solutions	 (erythromycin,	 chlorhexidine	
and	 hydrogen	 peroxide).	 During	 routine	 exami-
nations,	 three	years	 after	 extractions,	panoramic	
radiograph	revealed	a	well-circumscribed	and	ra-
diolucent	lesion,	measuring	2.3x1.7	cm,	in	the	pos-
terior	 left	 side	 of	maxilla	 (Figure	 1)	 without	 any	
clinical	 sign	and	compatible	with	a	 residual	 cyst.	
Computed	tomography	showed	a	well	demarcated,	
unilocular	 and	 hypodense	 mass	 in	 the	 posterior	
left	side	of	maxilla,	measuring	1.3x1.1	cm	(Figure	
2).	 At	 this	 point,	 patient	 was	 not	 using	 bisphos-
phonate	anymore	(for	about	six	months)	but	CTX	
was	still	low.
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Figure 1 | Initial panoramic radiography.
Figure 2 | Initial computed tomography.
Surgical	 excision	 of	 the	 cystic	 lesion	 was	 in-
dicated	 only	 when	 CTX	 improvement	 was	 obser-
ved.	Hematologic	exams	 including	complete	blood	
count,	 prothrombin	 time,	 activated	 thromboplas-
tin	 time,	 aspartate	 transaminase	 (AST),	 alanine	
transaminase	 (ALT),	 urea	 and	 fasting	 blood	 glu-
cose	(FBG)	showed	normal	results.	Also,	CTX	was	
requested	 again,	 and	 the	 result	 was	 430	 pg/mL,	
which	 would	 represent	minimal	 risk	 for	MRONJ,	
according	to	Marx.6
During	 surgical	 procedure,	 intra-	 and	 extra-
-oral	antisepsis	was	made	with	chlorhexidine,	and	
local	anesthesia	was	performed	with	mepivacaine.	
Tissue	 incision	 and	 divulsion	 were	 performed	 on	
a	 minimally	 traumatic	 technique.	 A	 Lucas	 curet-
te	 was	 used	 to	 displace	 the	 cyst	 capsule	 and,	 af-
ter	 lesion	 excision,	 the	 affected	 site	 was	 irrigated	
with	 physiological	 saline	 solution,	 with	 posterior	
osteoplasty	 and	 continuous	 suture	 with	 nylon	 (4-
0).	 After	 surgical	 procedure,	 the	 patient	 received	
a	 prescription	 of	 oral	 clindamycin,	 300mg,	 for	 7	
days;	 oral	 nimesulide,	 100mg,	 for	 3	 days,	 sublin-
gual	trometamol,	10	mg,	for	3	days	and	mouthrinse	
with	0.12%	chlorhexidine.
Histopathological	 examination	 revealed	 an	
inflammatory	 cyst,	 lined	 with	 stratified	 squa-
mous	 epithelium,	 which	 showed	 hydropic	 dege-
neration,	 spongiosis	 and	hyperplastic	 areas.	The	
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connective	 tissue	 was	 fibrous	 with	 small	 caliber	
blood	 vessels,	 presenting	 predominantly	 mono-
nuclear	 inflammatory	 infiltrate	(Figure	3).	These	
characteristics	 confirmed	 the	 radiographic	 diag-
nosis	 of	 residual	 cyst.	 Follow-up	 appointments	
were	booked	weekly	 in	 the	first	 two	months	and	
periapical	surgery	are	considered	local	risk	factors	
for	this	condition.7	Duration	of	treatment,	as	well	as	
bisphosphonate	 type	 and	 route	 of	 administration	
can	also	be	included	as	risk	factors.	Although	the-
re	 is	no	 scientific	 evidence,	 diabetes,	 obesity,	 coa-
gulopathies,	anemia,	use	of	alcohol	and	tobacco	are	
pointed	out	as	possible	predisposing	factors.7
Figure 3 | Inflammatory cyst (H&E, original magnification X100). Figure 4 | Panoramic radiograph with good bone neoformation 
(three months after  surgical procedure).
Figure 5 | Intraoral view (one year after the surgical procedure).
panoramic	radiograph	revealed	partial	bone	neo-
formation	after	three	months	(Figure	4).	One	year	
after	 the	 surgical	 procedure,	 the	 patient	 showed	
normal	healing	of	the	surgical	wound	without	any	
sign	 of	 MRONJ	 (Figure	 5),	 and	 she	 is	 currently	
under	follow-up.
DISCUSSION
MRONJ	 is	 reported	as	an	 important	 complica-
tion	of	bisphosphonate	 therapy	especially	associa-
ted	with	 the	 use	 of	 aminobisphosphonates,	which	
is	 difficult	 to	 treat	 and	 can	 considerably	 impair	
the	 patient’s	 quality	 of	 life.	 Periodontal	 disease,	
tooth	 extractions,	 dental	 implants	 placement,	 and	
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Many	 hypotheses	 have	 been	 postula-
ted	 to	 explain	 the	 pathogenesis	 of	 MRONJ.	
Bisphosphonates	are	able	 to	 interfere	with	remo-
deling	of	bone	tissue	by	acting	on	different	cells.8,9 
Their	 effect	 on	 osteoclasts	 occurs	 by	 inhibiting	
recruitment	 and	 differentiation,	 decreasing	 life	
span	 and	 promoting	 apoptosis.	 The	 presence	 of	
numerous	bacteria,	especially	Actinomyces	sp.,	in	
MRONJ	lesions	has	been	reported.8	Other	effects	
of	these	drugs,	such	as	impairment	of	both	angio-
genesis	 and	 epithelial	 cell	 proliferation,9	 support	
the	hypothesis	that	osteonecrosis	of	the	jaws	has	a	
multifactorial	etiology.	
Despite	 controversies,	 Ruggiero	 et	 al.2	 defend	
that	oral	bisphosphonate	users	who	need	oral	ma-
xillofacial	surgeries	should	undergo	a	drug	holiday	
and	bone	metabolism	monitoring	by	means	of	bio-
chemical	markers	such	as	the	serum	CTX	test.6	The	
American	 Association	 of	 Oral	 and	 Maxillofacial	
Surgeons	 (AAOMS)	 recommends	 that	 patients	
in	 use	 of	 oral	 bisphosphonates	 for	 three	 years	 or	
longer	 and	 using	 corticosteroids	 simultaneously	
should	 interrupt	 the	use	of	bisphosphonates	 three	
months	before	the	oral	surgery,	resuming	the	use	of	
the	drug	only	when	the	surgical	wound	is	comple-
tely	healed.6
It	 is	 important	 to	 highlight	 that	 the	 reported	
patient	 was	 successfully	 subjected	 to	 a	 surgical	
procedure	 to	 excise	 a	 residual	 cyst,	 even	with	 the	
previous	history	of	MRONJ.	Certainly,	drug	 inter-
ruption	contributed	to	our	successful	surgery,	since	
our	patient	stayed	three	years	without	alendronate	
use.	This	fact	is	confirmed	by	the	CTX	value,	which	
was	20	pg/mL	(high	risk	 for	MRONJ)	at	 the	 time	
patient	 developed	 MRONJ,	 and	 had	 increased	 to	
430	pg/mL	(minimal	risk)6	at	the	time	surgery	was	
performed.	Hence,	CTX	in	this	case	was	a	helpful	
tool	 for	 evaluating	 risk	 for	 MRONJ	 and	 guiding	
decisions	in	the	management	of	patients	under	bis-
phosphonate	therapy	who	need	maxillofacial	surgi-
cal	interventions.6
Although	bacterial	infection	might	accelerate	the	
development	of	MRONJ,	 it	 is	probably	not	 the	pri-
mary	 etiology	 for	 the	 condition	 since	MRONJ	was	
reported	spontaneously	without	prior	bone	exposure	
to	oral	microbiota.1	Nevertheless,	prophylaxis	proto-
cols	before	dental	intervention	for	patients	at	risk	of	
developing	MRONJ	may	have	a	significant	beneficial	
effect	in	the	prevention	of	secondary	infection	asso-
ciated	with	MRONJ.2	Lodi	et	al.10	reported	minimal	
post	 operatory	 complications	 associated	 with	 38	
dental	extractions	in	23	patients	receiving	bisphos-
phonate	therapy	and	treated	with	amoxicillin	(1	g,	3	
times/day)	1	day	before	dental	intervention	and	con-
tinued	 for	 17	days.	Although	 there	 is	no	consensus	
in	the	literature	about	this	protocol,	penicillin	is	the	
antibiotic	of	choice	for	prophylactic	and	post	opera-
tory	use	 in	oral	surgery	 in	patients	at	 risk	of	deve-
loping	MRONJ.6,10	In	this	case	it	was	not	prescribed	
amoxicillin	before	the	surgical	procedure.
We	 have	 reported	 here	 a	 well-succeeded	 sur-
gical	 excision	 of	 a	 residual	 cyst	 in	 a	 patient	 who	
had	previously	developed	MRONJ	associated	with	
sodium	 alendronate	 use.	 Despite	 the	 evidence	 of	
the	risks,	maxillofacial	surgeries	are	often	deman-
ded	 by	 patients	 under	 bisphosphonate	 therapy.	
Moreover,	 although	 rare,	MRONJ	 associated	with	
oral	 bisphosphonate	 does	 happen.	 Therefore,	 the	
correct	 approaching	 of	 the	 patient	 can	 provide	 a	
safe	procedure	avoiding	MRONJ	occurrence.	Also,	
the	need	for	 identifying	treatment	protocols	capa-
ble	of	reducing	the	incidence	of	this	oral	disease	is	
ever	more	pressing.
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